All
Global access to the DataSpace
The CAVD DataSpace is now open to the broader scientific community beyond those affiliated with the CAVD and the invited networks. Under this expanded membership, all members, including the public, have access to the complete set of HIV vaccine study pages in the DataSpace, and to data that have been designated by contributing networks for public access. For more information about public access to the DataSpace, read our blog, An Open DataSpace. Read more
An Open DataSpace
When we launched the CAVD DataSpace in December 2015, DataSpace membership included active and former members of the CAVD. In the fall of 2017, we invited members from HIV vaccine networks beyond the CAVD to join the DataSpace. Since then, we've been reaching out to networks to identify target members who'd benefit the most from accessing the DataSpace, specifically, investigators, junior investigators, staff scientists, and post docs involved in concept… Read more
New data uploads - June 2018
Data has been uploaded for 3 animal studies including: Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies. Name & Description Data Added Type PI Strategy CAVD 443 is a preclinical rabbit study comparing Vesicular Stomatitis Virus (VSV) vector, DNA, and protein regimens with and without adjuvant NAB Pre-Clinical NHP Parks Combo: DNA, protein & vector vaccines CAVD 487 (MU11) is a preclinical mouse study to… Read more
Data export improvements
We've updated some of the Export features in the Data Grid to make it more efficient to export the data out of DataSpace and explore in your own tools. Here's a summary of what's changed: As a reminder, your workbook or zip files contain additional metadata and information about the studies and data you've exported, including: Read more
Durability analysis for NYVAC challenge study timing
VISC statistician, Bryan Mayer, used data from 4 NHP studies testing NYVAC products (CAVD 259, CAVD 277, CAVD 281, and CAVD 434) to inform the design of an upcoming challenge study. Data on the duration of immune responses from the Binding Antibody Multiplex Assay (BAMA), Intracellular Cytokine Staining (ICS), and Neutralizing Antibody (nAb) TZM-bl assays were explored to help define a timeframe for challenge administration during which responses are still… Read more
MAb data? You betcha!
The DataSpace team has been busy processing the neutralizing antibody data from monoclonal antibody (mAb) screening and characterization studies. We aim to have mAb data available in DataSpace for exploration by late summer/early fall. Here's a mock-up of the new mAb section we are developing for the DataSpace. Using this summary view, you'll be able to: If you have experience (and/or an interest) in mAb nAb data and would like to participate in the working group,… Read more
MAb characterization data is coming soon!
We're organizing a working group to provide feedback and guidance for incorporation of neutralizing antibody (nAb) data from monoclonal antibody (mAb) screening and characterization studies. The group will review the planned implementation in DataSpace and discuss topics such as: If you have experience (or an interest) in mAb nAb data and would like to participate in the working group, contact [email protected]. Read more
New data uploads - November 2017
Data has been uploaded for 3 Ph I/II clinical trials, 7 NHP studies, and 3 other animal studies including: Click on the study page links below for Protocol Team reports, data summaries, and more details about the studies. Name & Description Data Added Type PI Strategy CAVD 256 (EV03/ANRSVAC20) is Phase I/II study to compare the immunogenicity and safety of 3 DNA-C prime followed by 1 NYVAC-C boost to 2 DNA-C prime followed by 2 NYVAC-C boost BAMA Phase I/II Pantaleo Combo: DNA… Read more
See you at the CAVD Annual Meeting!
Stop by our demo station on the lower level. That's OK. We'd love to hear from you. Contact us at [email protected]. Read more
Sample size calculation for CAVD 641
Here, we illustrate a sample size calculation using data from the CAVD DataSpace. In this study, our objective was to estimate sample size for a SOSIPv4.1 trimer vaccine study, CAVD 641, comparing the following adjuvants: Alum-3M052, administered via subcutaneous and intramuscular routes, versus GLA-LSQ administered via the intramuscular route. The outcome of interest was viral ID50 neutralization titer measured using the TZM-bl neutralization assay. There are… Read more
Results from CAVD 434/AUP 567
Using data available in the DataSpace, VISC statisticians, Bryan Mayer and Jimmy Fulp, generated a new report reproducing the CAVD 434/AUP 567 study results published in the May 2017 issue of the Journal of Virology. The report provides a brief tutorial showing how they used DataSpaceR to access and analyze the CAVD 434 data. As an alternative to the export feature in the Grid, we’ve created an R package that simplifies access to the DataSpace database. DataSpaceR is a… Read more
Pantaleo CAVD 434/AUP 567 publication and data
CAVD 434/AUP 567 study results were published in the May 2017 issue of the Journal of Virology. Zurawski G, Shen X, Zurawski S, Tomaras GD, Montefiori DC, Roederer M, Ferrari G, Lacabaratz C, Klucar P, Wang Z, Foulds KE, Kao SF, Yu X, Sato A, Yates NL, LaBranche C, Stanfield-Oakley S, Kibler K, Jacobs B, Salazar A, Self S, Fulp W, Gottardo R, Galmin L, Weiss D, Cristillo A, Pantaleo G, Levy Y. Superiority in Rhesus Macaques of Targeting HIV-1 Env gp140 to CD40 versus LOX-1 in… Read more